RTS, S, developed by GlaxoSmithKline (GSK), a British pharmaceutical company, will help.

这个新武器就是由英国制药公司葛兰素史克公司(GlaxoSmithKline研制的RTS，S。

Even then, it is unclear how RTS, S might be deployed.

即使到那时候，还不清楚RTS.S会怎样投放。

RTS, S combines a circumsporozoite protein, which exists on the parasite's surface, with a protein from a hepatitis B vaccine.

RTS, S把存在于寄生虫表面的环子孢子蛋白和肝炎B型疫苗里的一种蛋白结合在一起。

GSK hopes to induce a stronger immune response by combining RTS, S with a vaccine from Crucell, another drug firm.

葛兰素史克公司希望使用RTS，S和另一家制药公司Crucell的一种疫苗的结合体来引起更强烈的免疫反应。

It said that the jab, called RTS, S and made by GlaxoSmithKline, was safe and reduced by 30% cases of severe malaria in young children.

该组织称，这种由葛兰素史克公司生产的名为RTS, S的疫苗是安全的，可使幼儿严重疟疾的病例减少30%。

This efficacy was “on the positive side of what we were expecting, ” says Christian Loucq of the PATH Malaria Vaccine Initiative, GSK's partner on RTS, S.

葛兰素史克公司在研制RTS.S的搭档“疟疾疫苗开发计划”的Christian Loucq说这种效力“是我们曾期待的积极一面”。

The RTS vaccine prevents the malaria parasite from infecting, maturing and multiplying in the liver, from which it normally re-enters the blood and infects red blood cells, leading to the disease.

这种RTS疫苗能够防止肝脏内的疟原虫感染, 变成熟及增加, 它通常会再次进入血液及感染红细胞, 导致疾病。